UBS Downgrades Pharmasset (VRUS) to Neutral

June 2, 2009 2:55 PM EDT

UBS downgrades Pharmasset (Nasdaq: VRUS) from Buy to Neutral.

Traders are shrugging off the UBS downgrade today, and buying shares of Pharmasset. The stock most recently traded at $10.49, up 3%.

Pharmasset, Inc., a clinical-stage pharmaceutical company, focuses on discovering, developing, and commercializing drugs to treat viral infections.


Related Categories

Downgrades

Stocks Mentioned

VRUS 21.10

+1.30 +6.57%
Volume: 61,766
Track VRUS


Related Entities


Add Your Comment